ROCKY HILL, Conn. (PRWEB) July 01, 2020
Lumeda Inc. (“Lumeda”), a biophotonics systems company advancing photodynamic therapy (PDT) for treating cancer, today announced the formation of its Scientific Advisory Board with the appointment of a panel of medical and scientific experts who will provide critical medical, scientific, and strategic advice to support company development and introduction of its PDT products to the clinic. The three charter members appointed are:
Dr. Justin D. Blasberg MD, MPH, FACS, Associate Professor of Surgery and Director of Robotic Thoracic Surgery at Yale School of Medicine. As a skilled surgeon, Dr. Blasberg performs the majority of his surgeries in a minimally invasive fashion. He leads a clinical research program on novel imaging techniques for the detection of lung cancer and surgical outcomes research in thoracic surgery.
Dr. Michael M. Conway MD, is a medical executive and Pulmonary Disease and Internal Medicine specialist practicing in Hartford, CT and affiliated with Hartford Hospital. A recognized pulmonary expert with strong regional ties, Dr. Conway brings to Lumeda significant knowledge and expertise in diagnosing and staging of respiratory cancers, and associated standards of care and treatment options.
Dr. Gal Shafirstein DSc, Professor of Oncology and Director of PDT Clinical Research at Roswell Park Comprehensive Cancer Center. Dr. Shafirstein leads PDT translational and clinical research at Roswell Park focused on treatment planning and light dosimetry for interstitial and intraoperative PDT. He is the principal investigator and inventor on the intraoperative PDT innovation for treating lung cancer that Lumeda is commercializing.
“We are very pleased to have such accomplished medical and scientific professionals augment our team to advance this important lung cancer therapy,” according to Paul Sanders, one of the founders of Lumeda. “This advisory group brings a broad range of expertise that is critical to Lumeda’s product design and longer term strategy”.
This panel of medical and PDT science experts was carefully chosen and augments the company photonics engineering and development capabilities to advance its PDT product design for treatment effectiveness and fitness for use in the operating room environment.
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use, and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with significant expertise and strength in systems engineering, factory operations, and the commercialization of new products and technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit https://lumedainc.com